Skip to content

EBIT at other companies

Bausch Health Companies logo
Bausch Health CompaniesBHC
-$950M-444%
XER
Xeris Biopharma Holdings, Inc.XERS
$7.92M+356%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$2.41M+614%
Amgen logo
AmgenAMGN
AbbVie logo
AbbVieABBV
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX

Other financials

Income statement

See full
Revenue$94.5M+27.5%
Gross profit$89.7M+45.1%
Operating income-$32.8M+9.8%
Net income-$37.6M+8.6%
EPS (diluted)-$0.15+11.8%

Balance sheet

See full
Cash & equivalents$31.2M+1.3%
Total debt$208.3M+34.3%
Total equity$148.6M+2.0%
Total assets$504.5M+23.0%

Cash flow

See full
Operating cash flow-$32.2M+16.2%
CapEx$69.0K-78.8%
Free cash flow-$32.3M+16.7%

Valuation

See full
Market cap$1.53B+79.5%
Enterprise value$1.71B+74.8%
P/S3.6×+1.2×

Profitability

See full
Gross margin92.5%+7.9pp
Operating margin-25.4%
Net margin-13.6%
FCF margin-40.9%

Returns & leverage

See full
Return on equity-39.5%
Debt / equity1.4×+0.3×
Current ratio3.5×-0.6×

Where this comes from

Calculated from Ardelyx’s reported figures.

The official record: Ardelyx’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ardelyx's ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ardelyx's EBIT?
Ardelyx (ARDX) reported EBIT of -$32.79M in Q1 2026.
How has Ardelyx's EBIT changed year-over-year?
Ardelyx's EBIT increased by 9.8% year-over-year, from -$36.35M to -$32.79M.
What is the long-term trend for Ardelyx's EBIT?
Over 2 years (2021 to 2025), Ardelyx's EBIT has grown at a -48.6% compound annual growth rate (CAGR), from -$154.35M to -$40.72M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.